Figure 8. Proposed model for the role of the decoy antibody ACE2‐Fc in SARS‐CoV‐2 entry and infection.
The decoy antibody (ACE2‐Fc) not only reduces SARS‐CoV‐2 infection but also decreases TNF‐α secretion and ADAM‐17 phosphorylation mediated by angiotensin II. Ang II: angiotensin II; ARDS: acute respiratory distress syndrome; CatB/L: cathepsin B and L; PPRs: pattern recognition receptors; AMP: amplifier; STAT3: Signal transducer and activator of transcription 3; ATIR: angiotensin II type I receptor; ADAM17: a disintegrin and metalloprotease 17; TMPRSS2: transmembrane Serine Protease 2.